- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA's Global Strategy Against Counterfeit Medications
Earlier this month, the FDA took steps to prevent the online sale of counterfeit and illegal medicinal products, which can be a significant health risk to the population.
Earlier this month, the FDA took steps to prevent the online sale of counterfeit and illegal medicinal products, which can be a significant health risk to the population.
Operation Pangea VIII, which spanned 115 countries, resulted in more than 2400 websites being taken offline and the seizure of $81 million worth of potential dangerous illegal medicines and medical devices worldwide. The current effort was a part of FDA's Global Strategic Framework for counterfeit and substandard medical products that strives to protect consumers by reducing their exposure to counterfeit and substandard medical products.
Read more about the FDA's effort on FDAVoice.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
